Introduction: Vitamin D deficiency is highly prevalent among patients with inflammatory bowel disease (IBD) and has been associated with increased disease activity, impaired mucosal healing, reduced quality of life, and higher healthcare utilization. Beyond its established role in bone health, vitamin D exerts important immunomodulatory effects that may influence intestinal inflammation.
Introduction:
Vitamin D deficiency is highly prevalent among patients with inflammatory bowel disease (IBD) and has been associated with increased disease activity, impaired mucosal healing, reduced quality of life, and higher healthcare utilization. Beyond its established role in bone health, vitamin D exerts important immunomodulatory effects that may influence intestinal inflammation. Despite these biological advantages, the real-world clinical benefits of vitamin D supplementation in IBD have remained uncertain.
Problem Statement:
Although vitamin D deficiency is frequently identified and treated in patients with IBD, evidence supporting its impact on meaningful clinical outcomes such as corticosteroid requirements, emergency department visits, and hospitalizations is limited. Determining whether supplementation translates into measurable improvements in disease burden is important for optimizing routine IBD care.
Summary:
This large real-world study evaluated the impact of vitamin D supplementation on clinical outcomes in patients with IBD receiving care within a national healthcare system. The investigators found that vitamin D supplementation was associated with a reduction in IBD-related emergency department visits, hospitalizations, and corticosteroid use compared with patients who did not receive supplementation. These findings were consistent across multiple analytical approaches, strengthening the reliability of the observed associations. The study suggests that correction of vitamin D deficiency may contribute to improved disease control and reduced healthcare utilization in routine clinical practice. Given its low cost, favorable safety profile, and widespread availability, vitamin D supplementation represents an attractive adjunctive strategy in the management of IBD. Importantly, the benefits observed extended beyond laboratory correction of deficiency and were linked to clinically meaningful outcomes that directly affect patients and healthcare systems. While the observational nature of the study prevents definitive conclusions regarding causality, the results support a proactive approach to screening for and treating vitamin D deficiency in IBD populations. Future prospective trials are needed to determine optimal supplementation regimens, identify target vitamin D levels, and clarify the mechanisms through which vitamin D may influence long-term disease outcomes.
Introduction: The global incidence of inflammatory bowel disease (IBD) continues to rise, particularly in newly industrialized countries. This comprehensive systematic review evaluated how race, ethnicity, geography, and migration influence the clinical phenotype and outcomes of...
Introduction: Acute severe ulcerative colitis (ASUC) remains one of the most life-threatening emergencies in inflammatory bowel disease. Despite advances in IBD therapy, first-line management has changed little over the past two decades, and colectomy continues...
Introduction: Ulcerative colitis (UC) is a chronic inflammatory bowel disease with a rising global burden. Although current therapies are effective, many patients fail treatment or experience adverse effects. Fecal microbiota transplantation (FMT) has emerged as...
Introduction: Despite major advances with biologics and small molecules, many patients with IBD continue to have refractory disease or lose treatment response. This Perspective explores engineered cellular therapies designed to restore immune tolerance rather than...
Introduction: Randomized clinical trials (RCTs) are the cornerstone for approving biologic therapies in inflammatory bowel disease (IBD). However, strict eligibility criteria may exclude many patients encountered in routine clinical practice, raising concerns about the real-world...
Introduction: Mirikizumab, a selective IL-23p19 inhibitor, has demonstrated efficacy in phase III clinical trials for moderate-to-severe ulcerative colitis (UC). This multicenter Italian real-world study evaluated its effectiveness and safety in routine clinical practice, including patients...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.